137 related articles for article (PubMed ID: 38886096)
1. Efficacy in diet-induced obese mice of the hepatotropic, peripheral cannabinoid 1 receptor inverse agonist TM38837.
Cooper ME; Nørregaard PK; Högberg T; Andersson G; Receveur JM; Linget JM; Elling CE
Br J Pharmacol; 2024 Jun; ():. PubMed ID: 38886096
[TBL] [Abstract][Full Text] [Related]
2. Optimizing and characterizing 4-methyl substituted pyrazol-3-carboxamides leading to the peripheral cannabinoid 1 receptor inverse agonist TM38837.
Högberg T; Receveur JM; Murray A; Linget JM; Nørregaard PK; Little PB; Cooper M
Bioorg Med Chem Lett; 2024 Jan; 98():129572. PubMed ID: 38043690
[TBL] [Abstract][Full Text] [Related]
3. The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice.
Micale V; Drago F; Noerregaard PK; Elling CE; Wotjak CT
Front Pharmacol; 2019; 10():207. PubMed ID: 30949045
[TBL] [Abstract][Full Text] [Related]
4. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
[TBL] [Abstract][Full Text] [Related]
5. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
Jacobson LH; Commerford SR; Gerber SP; Chen YA; Dardik B; Chaperon F; Schwartzkopf C; Nguyen-Tran V; Hollenbeck T; McNamara P; He X; Liu H; Seidel HM; Jaton AL; Gromada J; Teixeira S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
[TBL] [Abstract][Full Text] [Related]
7. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
Son MH; Kim HD; Chae YN; Kim MK; Shin CY; Ahn GJ; Choi SH; Yang EK; Park KJ; Chae HW; Moon HS; Kim SH; Shin YG; Yoon SH
Int J Obes (Lond); 2010 Mar; 34(3):547-56. PubMed ID: 20029379
[TBL] [Abstract][Full Text] [Related]
8. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
Nogueiras R; Veyrat-Durebex C; Suchanek PM; Klein M; Tschöp J; Caldwell C; Woods SC; Wittmann G; Watanabe M; Liposits Z; Fekete C; Reizes O; Rohner-Jeanrenaud F; Tschöp MH
Diabetes; 2008 Nov; 57(11):2977-91. PubMed ID: 18716045
[TBL] [Abstract][Full Text] [Related]
9. Peripherally restricted CB1 receptor blockers.
Chorvat RJ
Bioorg Med Chem Lett; 2013 Sep; 23(17):4751-60. PubMed ID: 23902803
[TBL] [Abstract][Full Text] [Related]
10. The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.
Cooper ME; Regnell SE
Br J Clin Pharmacol; 2014 Jan; 77(1):21-30. PubMed ID: 23452341
[TBL] [Abstract][Full Text] [Related]
11. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid CB
Chen W; Liu H; Guan H; Xue N; Wang L
Eur J Pharmacol; 2017 Nov; 814():232-239. PubMed ID: 28844874
[TBL] [Abstract][Full Text] [Related]
13. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight.
Engeli S
Handb Exp Pharmacol; 2012; (209):357-81. PubMed ID: 22249824
[TBL] [Abstract][Full Text] [Related]
14. Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
Matthews JM; McNally JJ; Connolly PJ; Xia M; Zhu B; Black S; Chen C; Hou C; Liang Y; Tang Y; Macielag MJ
Bioorg Med Chem Lett; 2016 Nov; 26(21):5346-5349. PubMed ID: 27671496
[TBL] [Abstract][Full Text] [Related]
15. The Peripheral Cannabinoid Receptor Type 1 (CB
O'Sullivan SE; Yates AS; Porter RK
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684760
[TBL] [Abstract][Full Text] [Related]
16. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
[TBL] [Abstract][Full Text] [Related]
17. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides.
Cinar R; Godlewski G; Liu J; Tam J; Jourdan T; Mukhopadhyay B; Harvey-White J; Kunos G
Hepatology; 2014 Jan; 59(1):143-53. PubMed ID: 23832510
[TBL] [Abstract][Full Text] [Related]
18. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
[TBL] [Abstract][Full Text] [Related]
19. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
[TBL] [Abstract][Full Text] [Related]
20. Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.
Lu D; Dopart R; Kendall DA
Cell Stress Chaperones; 2016 Jan; 21(1):1-7. PubMed ID: 26498013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]